Literature DB >> 20200042

Metformin attenuates cardiac fibrosis by inhibiting the TGFbeta1-Smad3 signalling pathway.

Han Xiao1, Xiaowei Ma, Wei Feng, Yongnan Fu, Zhizhen Lu, Ming Xu, Qiang Shen, Yi Zhu, Youyi Zhang.   

Abstract

AIMS: The mechanism of the cardioprotective action of metformin is incompletely understood. We determined the role of metformin in cardiac fibrosis and investigated the mechanism. METHODS AND
RESULTS: Ten-week-old male mice (C57BL/6) were subjected to left ventricular pressure overload by transverse aortic constriction. Mice received metformin (200 mg/kg/day) or normal saline for 6 weeks. Metformin inhibited cardiac fibrosis (fibrosis area/total heart area: 0.6 +/- 0.3 vs. 3.6 +/- 0.9%, P < 0.01) induced by pressure overload and improved cardiac diastolic function (left ventricular end-diastolic pressure: 5.2 +/- 0.9 vs. 11.0 +/- 1.6 mmHg, P < 0.05). Metformin inhibited the pressure overload-induced transforming growth factor (TGF)-beta(1) production in mouse hearts and the TGF-beta(1)-induced collagen synthesis in cultured adult mouse cardiac fibroblasts (CFs). Metformin suppressed the phosphorylation of Smad3 in response to TGF-beta(1) in CFs. Metformin also inhibited the nuclear translocation and transcriptional activity of Smad3 in CFs.
CONCLUSION: Metformin inhibited cardiac fibrosis induced by pressure overload in vivo and inhibited collagen synthesis in CFs probably via inhibition of the TGF-beta(1)-Smad3 signalling pathway. These findings provide a new mechanism for the cardioprotective effects of metformin.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20200042     DOI: 10.1093/cvr/cvq066

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  74 in total

1.  Phenolic secoiridoids in extra virgin olive oil impede fibrogenic and oncogenic epithelial-to-mesenchymal transition: extra virgin olive oil as a source of novel antiaging phytochemicals.

Authors:  Alejandro Vazquez-Martin; Salvador Fernández-Arroyo; Sílvia Cufí; Cristina Oliveras-Ferraros; Jesús Lozano-Sánchez; Luciano Vellón; Vicente Micol; Jorge Joven; Antonio Segura-Carretero; Javier A Menendez
Journal:  Rejuvenation Res       Date:  2012-01-09       Impact factor: 4.663

Review 2.  Cardiac metabolism in heart failure: implications beyond ATP production.

Authors:  Torsten Doenst; Tien Dung Nguyen; E Dale Abel
Journal:  Circ Res       Date:  2013-08-30       Impact factor: 17.367

3.  The role of metformin and resveratrol in the prevention of hypoxia-inducible factor 1α accumulation and fibrosis in hypoxic adipose tissue.

Authors:  Xiaole Li; Jia Li; Lulu Wang; Aiyun Li; Zhixia Qiu; Lian-Wen Qi; Junping Kou; Kang Liu; Baolin Liu; Fang Huang
Journal:  Br J Pharmacol       Date:  2016-05-15       Impact factor: 8.739

4.  Atheroprone flow enhances the endothelial-to-mesenchymal transition.

Authors:  Baochang Lai; Zhao Li; Ming He; Yili Wang; Lili Chen; Jiao Zhang; Yan Yang; John Y-J Shyy
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-07-27       Impact factor: 4.733

5.  Metformin: Midlife maturity, maiden charm.

Authors:  Sanjay Kalra; Puneet Dhamija; Ashok K Das
Journal:  Indian J Endocrinol Metab       Date:  2012-11

Review 6.  Metformin therapy in diabetes: the role of cardioprotection.

Authors:  Saloua El Messaoudi; Gerard A Rongen; Niels P Riksen
Journal:  Curr Atheroscler Rep       Date:  2013-04       Impact factor: 5.113

7.  Metformin in Diabetic Patients with Heart Failure: Safe and Effective?

Authors:  Ijeoma Ananaba Ekeruo; Amirreza Solhpour; Heinrich Taegtmeyer
Journal:  Curr Cardiovasc Risk Rep       Date:  2013-12-01

Review 8.  Congestive heart failure and diabetes mellitus: balancing glycemic control with heart failure improvement.

Authors:  Saifullah Nasir; David Aguilar
Journal:  Am J Cardiol       Date:  2012-11-06       Impact factor: 2.778

Review 9.  Heart Failure in Type 2 Diabetes Mellitus.

Authors:  Helena C Kenny; E Dale Abel
Journal:  Circ Res       Date:  2019-01-04       Impact factor: 17.367

10.  Metformin protects against systolic overload-induced heart failure independent of AMP-activated protein kinase α2.

Authors:  Xin Xu; Zhongbing Lu; John Fassett; Ping Zhang; Xinli Hu; Xiaoyu Liu; Dongmin Kwak; Jingxin Li; Guangshuo Zhu; Yi Tao; Mingxiao Hou; Huan Wang; Haipeng Guo; Benoit Viollet; Edward O McFalls; Robert J Bache; Yingjie Chen
Journal:  Hypertension       Date:  2014-01-13       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.